The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By

GI Alliance

Advising the management and majority physician owners of GI Alliance, the largest gastroenterology practice in the United States, on its recapitalization and buyout of minority partner, Waud Capital

Liontown Resources

Advised Liontown Resources, an ASX-listed lithium company focused on the development of the world-class Kathleen Valley Lithium Project, on a lithium spodumene concentrate offtake agreement and A$300m financing facility from Ford Motor Company

Syrah Resources

Advisor to Syrah Resources, an ASX-listed industrial minerals and technology company, on its US$107mm loan from the U.S. Department of Energy under the Advanced Technology Vehicles Manufacturing loan program to fund the initial expansion of its Vidalia active anode material facility in Louisiana, USA

DGO Gold

Advising DGO Gold, an ASX-listed gold exploration company, on its recommended, off-market takeover offer from Gold Road Resources, an ASX-listed gold producer

Theramex

Advising Carlyle, the leading private equity investor, on the acquisition of Theramex, a Women’s health-focused specialty pharmaceutical company . The acquisition was jointly executed with PAI Partners

Acacia Pharma Group plc

Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise

Liontown Resources

Advised Liontown Resources, an ASX-listed lithium company focused on the development of the world class Kathleen Valley Lithium Project, on a lithium spodumene concentrate offtake agreement with Tesla, a major electric vehicle manufacturer

Alteon Health

Advised Alteon Health, a portfolio company of New Mountain Capital and national physician-led provider of emergency medicine, hospitalist medicine and post-acute care services, on its sale to U.S. Acute Care Solutions

Akorn Pharmaceuticals Portfolio of Branded Ophthalmic Products

Advised Akorn Pharmaceuticals, a specialty pharmaceuticals manufacturer and marketer, on the divestiture of its portfolio of branded ophthalmic products to Laboratoires Théa SAS

Liontown Resources

Advised Liontown Resources, an ASX-listed lithium company focused on the development of the world class Kathleen Valley Lithium Project, on a lithium spodumene concentrate offtake agreement with LG Energy Solutions, a major South Korean-based EV battery supplier for leading global automakers

Syrah Resources

Advised Syrah Resources, an ASX-listed industrial minerals and technology company, on a natural graphite active anode material offtake agreement with Tesla, the world’s largest EV manufacturer

Japan Medical Dynamic Marketing

Advising Mitsui Chemicals, one of the largest Japanese chemical companies, on the acquisition of a 30% stake in Japan Medical Dynamic Marketing, a leading orthopedic medical device manufacturer in Japan, held by NGK SPARK PLUG

Liontown Resources

Advised Liontown Resources, an ASX-listed lithium company focused on the development of the world class Kathleen Valley Lithium Project, on its A$490m equity raising, comprised of a fully underwritten placement of A$450m and a non-underwritten share purchase plan of A$40m

MetalX, Inc.

Advised MetalX, Inc., a leading ferrous and non-ferrous metal scrap recycling company, on the sale of substantially all of its ferrous scrap processing business to BlueScope Steel Limited, an Australian-listed provider of steel materials, products, systems and technologies

Millennial Lithium

Advised Lithium Americas, a development-stage company with projects in Jujuy, Argentina and Nevada, United States on its acquisition of Millennial Lithium, a Vancouver-based exploration and development company focused on advancing the Pastos Grandes Lithium Project in Argentina

Metro Quarry Group

Advised Myer Family Investments on the sale of the assets of Metro Quarry Group (Victoria’s largest specialist sand quarry) to a joint venture comprising Adbri / Barro Group

Procaps Group

Advised Procaps Group, a leading integrated international healthcare and pharmaceutical company, on its successful business combination with Union Acquisition Corp II (NASDAQ: LATN), a LatAm-focused special purpose acquisition company. Procaps Group now trades on the Nasdaq Global Market under the ticker symbol "PROC"

Faes Farma, flagship product Bilastine

Advised Faes Farma in the signing of a long-term license agreement for its flagship product Bilastine with Hikma Specialty USA INC, a subsidiary of Hikma Pharmaceuticals PLC, for the United States of America

New Day Aluminum LLC

Advised DADA Holdings on the sale of its majority stake in New Day Aluminum LLC to Concord Resources Ltd.

Deltalab

Advising Deltalab, a leading Spanish laboratory solutions provider with dedicated manufacturing capacity, on the sale of the company to SCG Packaging Public Company Limited, the largest integrated packaging and paper company in Southeast Asia

Portfolio of 16 European Consumer Healthcare brands from Sanofi

Advising Sanofi, a leading global player in the Consumer Healthcare market, on the divestiture of a portfolio of 16 European Consumer Healthcare brands to STADA, a German pharmaceutical and consumer healthcare company owned by Bain Capital and Cinven

VEP Healthcare

Advised VEP Healthcare, a leading, physician-owned provider of clinical management services in emergent and inpatient settings in the United States, on its merger with U.S. Acute Care Solutions

MindPath Care Centers

Advised Community Psychiatry, a leading provider of outpatient behavioral health services with a focus on high-quality clinically-driven care, on its acquisition of MindPath Care Centers, deepening its national presence to more than 350 providers across the US

MDLIVE

Advising Cigna on the acquisition of MDLIVE, a virtual care delivery platform, by Evernorth, Cigna’s health services portfolio

Acacia Pharma Group plc

Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share